Management of Systemic Lupus Erythematosus with Persistent C3 Deficiency, Normalized C4, and Fever

Infection Assessment

Perform a comprehensive infection work‑up—including blood cultures, urine cultures, chest radiography, and consider CMV testing in immunosuppressed patients—to rule out infection before intensifying immunosuppression. 1
Recognize severe neutropenia, severe lymphopenia, and low IgG levels as major risk factors for infection in SLE patients. 2
Treat any confirmed infection aggressively and, for severe infections, temporarily reduce immunosuppressive agents. 1

Persistent low C3 with normal C4 signals ongoing disease activity and may necessitate therapeutic adjustment. 2
Systematically evaluate new or worsening clinical manifestations such as cutaneous rash, active arthritis, serositis, neuro‑psychiatric features, and renal involvement. 1
Monitor laboratory markers of activity—including complete blood count, serum creatinine, proteinuria, urine sediment, and anti‑dsDNA antibodies—to gauge disease status. 2
Apply validated disease‑activity indices (e.g., SLEDAI) for standardized assessment. 1

Ensure hydroxychloroquine is dosed at ≈ 5 mg/kg of actual body weight per day, not exceeding 400 mg/day, as recommended by the American College of Rheumatology (ACR). 3
Measure hydroxychloroquine blood levels (target > 0.6 mg/L) to confirm adherence and adequate exposure. 2
Do not discontinue hydroxychloroquine unless a specific contraindication exists, because cessation raises flare risk by roughly 2.5‑fold. 5

For moderate‑to‑severe flares, administer intravenous methylprednisolone pulses of 250–1000 mg/day for 1–3 days to achieve rapid control (ACR guidance). 4
Maintain oral glucocorticoid therapy at ≤5–7.5 mg/day prednisone‑equivalent to minimize long‑term toxicity. 4
Avoid prolonged continuous glucocorticoid doses >7.5 mg/day, as adverse‑event risk rises substantially above this threshold. 1

Add or intensify conventional agents—mycophenolate mofetil, azathioprine, or methotrexate—to facilitate glucocorticoid tapering in patients with persistent activity despite belimumab (ACR recommendations). 3
Consider rituximab for organ‑threatening or refractory disease. 4
Use cyclophosphamide as rescue therapy in severe organ‑threatening manifestations. 4

In patients with suspected renal disease, evaluate serum creatinine, quantitative proteinuria, and urine sediment. 1
For active lupus nephritis, initiate mycophenolate mofetil (2–3 g/day) or low‑dose intravenous cyclophosphamide combined with glucocorticoids (ACR guidance). 4

Aim for remission or low disease activity as defined by ACR criteria. 3
Perform regular disease‑activity monitoring using validated indices (e.g., SLEDAI). 1
Allow 6–12 months to assess therapeutic response, especially for renal outcomes, because proteinuria declines slowly. 2

Do not empirically increase immunosuppression solely on the basis of fever without a thorough infection evaluation. 1
Avoid premature changes to the therapeutic regimen; give the current treatment an adequate trial period before modification. 2
Maintain hydroxychloroquine therapy whenever possible to prevent a marked increase in flare risk. 5